The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro

Journal Title: European Journal of Gynaecological Oncology - Year 2019, Vol 40, Issue 1

Abstract

Purpose of investigation: The pleiotropic factor Y-box binding protein-1 (YB-1) is clinically correlated with breast cancer patients’ poor outcome. Due to the intereference of YB-1 with the estrogen receptor, the authors examined the antiproliferative efficacy of 4-hydroxytamoxifen (4-OHT) and fulvestrant (FUL) in the presence of low and high levels of YB-1. Materials and Methods: The human breast cancer cell line MCF-7 was transfected to overexpress YB-1 protein. 4- OHT and FUL incubation experiments were performed and cell growth behaviour of YB-1 overexpressing MCF-7 cells were compared to unmodified MCF-7 cells expressing endogenous YB-1 levels. Results: The incubation of MCF-7 cells with 100 nM 4-OHT and 1 nM FUL over a period of 120 hours clearly demonstrated the antiproliferative properties of both antiestrogens as expected. Notably, high levels of YB-1 led to an increase of antiproliferative properties in the presence of 4-OHT and FUL. Conclusion: The data presented here demonstrated YB-1 enhances the antiestrogenic efficacy of 4- OHT and FUL. Thus, the group of high level YB-1 mamma carcinoma patients might increasingly benefit from endocrine therapy.

Authors and Affiliations

M. B. Stope, M. Weiss, S. L. Popp, C. Joffroy, A. Mustea, S. Brucker, D. Wallwiener

Keywords

Related Articles

Plasma fibrinogen, CRP, and hs-CRP levels in patients with benign and borderline ovarian tumours

Objective: Ovarian tumours can be classified as benign, borderline or malignant lesions. The purpose of this study was to assess, inter alia, fibrinogen concentration, and the (C-reactive proteins) and high-sensitivity C...

The role of erythropoietin and erythropoietin receptor expression in breast cancer

Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results con...

The association of microcystic, elongated, and fragmented (MELF) invasion pattern in endometrial carcinomas with prognostic factors

Purpose: One of the most important prognostic factors for endometrial carcinoma (EC) is myometrial invasion. Microcystic, elongated, and fragmented (MELF) myometrial invasion (MI) pattern is also important in terms of di...

Clinical features and prognostic factors associated with malignant transformation of ovarian mature cystic teratoma

Purpose: To explore the clinical characteristics and identify potential prognostic factors associated with malignant transformation (MT) of ovarian mature cystic teratoma (MCT). Materials and Methods: This study analyzed...

Expression of FOXA1 in breast cancer and the significance

Objective: The aim of this study to examine the expression of FOXA1, ER, and PR in breast cancer and investigate the association between FOXA1 expression and clinical parameters. Materials and Methods: One hundred one ca...

Download PDF file
  • EP ID EP626296
  • DOI 10.12892/ejgo4282.2019
  • Views 54
  • Downloads 0

How To Cite

M. B. Stope, M. Weiss, S. L. Popp, C. Joffroy, A. Mustea, S. Brucker, D. Wallwiener (2019). The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro. European Journal of Gynaecological Oncology, 40(1), 16-18. https://europub.co.uk/articles/-A-626296